Mirum Pharmaceuticals(MIRM)
Focus: Mirum Pharmaceuticals is a publicly traded specialty pharma company focused on small-molecule therapeutics for rare liver diseases and cholestatic disorders. The company generates $186M in revenue (FY 2025) with a highly concentrated portfolio anchored by CHOLBAM, which represents 53% of revenue.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
75+30 this month
Hot — 60 jobs added in 30d
Net +30 (60 new, 30 removed). Aggressive expansion phase.
Should You Work at Mirum Pharmaceuticals?
AI assessmentHigh-growth niche player with strong equity upside potential but concentrated revenue base and execution risk; best for risk-tolerant professionals seeking rare-disease expertise and equity participation.
Why Work Here
- Commercial-heavy hiring (60 of 78 roles) signals aggressive market expansion for approved therapies with clear revenue trajectory ($186M FY2025, up 142% YoY).
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
10 Phase 3+
LOE Risk
1 imminent
CTEXLI
Hiring
Stable
Revenue
$186M
FY2025
Key Products
53% of total revenue (~$99M inferred FY2025)Growing
Peak
Anchor franchise driving company profitability; no LOE date signals long patent protection in rare pediatric disorder.
Help build intelligence for Mirum Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.